MA46620A - Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha - Google Patents
Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alphaInfo
- Publication number
- MA46620A MA46620A MA046620A MA46620A MA46620A MA 46620 A MA46620 A MA 46620A MA 046620 A MA046620 A MA 046620A MA 46620 A MA46620 A MA 46620A MA 46620 A MA46620 A MA 46620A
- Authority
- MA
- Morocco
- Prior art keywords
- modulators
- responses
- useful
- ifn alpha
- heterobicyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414158P | 2016-10-28 | 2016-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46620A true MA46620A (fr) | 2021-05-26 |
Family
ID=60263169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046620A MA46620A (fr) | 2016-10-28 | 2017-10-27 | Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10781215B2 (fr) |
| EP (1) | EP3532473B1 (fr) |
| JP (1) | JP7145850B2 (fr) |
| KR (1) | KR102477063B1 (fr) |
| CN (1) | CN110114357B (fr) |
| ES (1) | ES2895107T3 (fr) |
| MA (1) | MA46620A (fr) |
| WO (1) | WO2018081488A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7082120B2 (ja) | 2016-10-21 | 2022-06-07 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| TW201940483A (zh) | 2018-03-12 | 2019-10-16 | 美商艾伯維有限公司 | 酪胺酸激酶２介導的傳訊之抑制劑 |
| AR117177A1 (es) * | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| JP2022529311A (ja) * | 2019-03-26 | 2022-06-21 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| KR20220002488A (ko) | 2019-04-30 | 2022-01-06 | 셀진 코포레이션 | 아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법 |
| MX2022005563A (es) | 2019-11-08 | 2022-08-19 | Ventyx Biosciences Inc | Ligandos de la pseudoquinasa tyk2. |
| CN114901659A (zh) * | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
| CN116283993B (zh) * | 2021-12-20 | 2024-05-03 | 艾立康药业股份有限公司 | 一种嘧啶类化合物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| WO2008135232A1 (fr) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Utilisation et compositions de dérivés de purine pour le traitement de troubles prolifératifs |
| CN101827848B (zh) * | 2007-08-08 | 2012-11-07 | 葛兰素史密丝克莱恩有限责任公司 | 作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物 |
| EA018282B1 (ru) * | 2008-04-07 | 2013-06-28 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| CA2723185A1 (fr) * | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibiteurs de proteines kinases |
| CN104903301B (zh) * | 2012-11-08 | 2017-08-29 | 百时美施贵宝公司 | 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物 |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| ES2702126T3 (es) * | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| TW201625620A (zh) * | 2014-05-14 | 2016-07-16 | 美國科羅拉多州立大學 | 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法 |
| JP7082120B2 (ja) * | 2016-10-21 | 2022-06-07 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
-
2017
- 2017-10-27 CN CN201780080803.4A patent/CN110114357B/zh active Active
- 2017-10-27 EP EP17794645.6A patent/EP3532473B1/fr active Active
- 2017-10-27 ES ES17794645T patent/ES2895107T3/es active Active
- 2017-10-27 WO PCT/US2017/058645 patent/WO2018081488A1/fr unknown
- 2017-10-27 US US16/344,459 patent/US10781215B2/en active Active
- 2017-10-27 KR KR1020197014828A patent/KR102477063B1/ko active IP Right Grant
- 2017-10-27 MA MA046620A patent/MA46620A/fr unknown
- 2017-10-27 JP JP2019522803A patent/JP7145850B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110114357A (zh) | 2019-08-09 |
| WO2018081488A1 (fr) | 2018-05-03 |
| KR20190068614A (ko) | 2019-06-18 |
| KR102477063B1 (ko) | 2022-12-12 |
| EP3532473A1 (fr) | 2019-09-04 |
| US20190322672A1 (en) | 2019-10-24 |
| JP2019532092A (ja) | 2019-11-07 |
| CN110114357B (zh) | 2022-05-31 |
| ES2895107T3 (es) | 2022-02-17 |
| JP7145850B2 (ja) | 2022-10-03 |
| EP3532473B1 (fr) | 2021-09-29 |
| US10781215B2 (en) | 2020-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46620A (fr) | Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha | |
| MA46453A (fr) | Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha | |
| MA43512A (fr) | Composés hétérocycliques utiles en tant que modulateurs du tnf alpha | |
| DK3066078T3 (da) | Alkyl-amid-substituerede pyridylforbindelser, der er anvendelige som modulatorer af il-12-, il-23- og/eller ifn-alpha-responser | |
| BR112016025470A2 (pt) | ?hdl terapêutico? | |
| MA43314A (fr) | Vecteurs de grippe atténues utilisés pour la prophylaxie et/ou le traitement de maladies infectieuses ainsi que pour le traitement de maladies oncologiques | |
| FR3037236B1 (fr) | Microcapsules et composition de maquillage ou de tatouage thermochromiques | |
| MA48602A (fr) | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha | |
| MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate | |
| MA47516A (fr) | Composition pharmaceutique | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| MA45158A (fr) | Composition pharmaceutique comprenant de l'éteplirsen | |
| MA41120A (fr) | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci | |
| DK3279312T3 (da) | Biobeskyttelse af mejeriprodukter | |
| BR112017020230A2 (pt) | composições de recursos preferenciais por térmitas e métodos | |
| MA42552A (fr) | Compositions pharmaceutiques de flurbiprofène et de tramadol | |
| ITUA20163470A1 (it) | Formulazione antiappannante | |
| KR20220035421A (ko) | (s)-3-아미노-6-메톡시-n-피콜린아미드의 제형 | |
| MA53898A (fr) | Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament | |
| DK3630092T3 (da) | Formulering på basis af vitamin E eller en ester deraf til behandling af bakterie- og svampebiofilm | |
| FI20165823A (fi) | Siemenöljy, siemenöljyä käsittävä koostumus ja siemenöljyn käyttö | |
| CL2017000016A1 (es) | Administración intradérmica de una composición de inmunoglobulina g. | |
| FR3036754B1 (fr) | Mecanisme d'embrayage et gamme de mecanismes d'embrayage | |
| UA39416S (uk) | Комплект етикеток | |
| UA38480S (uk) | Комплект етикеток |